PMV Pharmaceuticals, Inc.

Plus, news about Interius BioTherapeutics, Hope Medicine, PMV Pharmaceuticals, Epitopea, Alyssum Therapeutics and a new dementia trial accelerator in the UK: Bayer exercises option to develop heart drug with Dewpoint Therapeutics : The companies, which first teamed up in 2019, now plan to develop a therapy for dilated cardiomyopathy, a heart muscle disease. Bayer is paying $424 million in upfront and milestone payments. — Jaimy Lee Viking Therapeutics is already thinking about an obesity launch: The company plans to meet with the FDA before the end of the year to discuss Phase 3 plans for its subcutaneous GLP-1/GIP receptor agonist, VK2735, according to remarks made by CEO Brian Lian on Wednesday’s earnings call. Viking is already in conversation with manufacturers, and Lian said he’s confident the company will be able to supply “a blockbuster-sized product at the appropriate time.” Viking is also launching a Phase 2 trial this quarter for an oral version of VK2735. Lian described the experimental oral medicine as more of an “add-on” to the portfolio, while the subcutaneous version would be the “anchor piece.” — Nicole DeFeudis Interius BioTherapeutics doses first ever patient with in vivo CAR-T: The biotech gave an in vivo CAR-T therapy to a patient enrolled in a Phase 1 study of INT2104, which it’s developing for B cell cancers. The trial, which is being run in Australia, is the first test of its kind. Umoja Biopharma has said it plans to dose a patient in its US-based study of its own in vivo CAR-T therapy by the end of this year . — Lei Lei Wu Hope Medicine touts interim data for endometriosis treatment: The company’s monoclonal antibody, dubbed HMI-115 , demonstrated statistically significant improvement in endometriosis pain at 12 weeks. The Phase 2 trial enrolled 142 female patients in the US, Poland and China. The mean dysmenorrhea pain score was reduced by 42%, and non-menstrual pelvic pain score was reduced by 50%. Hope CEO Nathan Chen said the company plans to “move quickly” toward global Phase 3 trials. — Katherine Lewin PMV Pharmaceuticals discontinues early-stage cancer trial: Citing toxicities and limited clinical benefit, the company abandoned its Phase 1b study assessing rezatapopt and Merck’s Keytruda. It had been testing the combo in patients with advanced solid tumors harboring a TP53 Y220C mutation. PMV said enrollment for a Phase 2 trial evaluating rezatapopt as a monotherapy for patients with TP53 Y220C and KRAS wild-type advanced solid tumors is still on track. — Katherine Lewin Epitopea closes $31M pre-Series A: With today’s round, the cancer biotech has raised more than $45 million. The funds are set to go toward its preclinical discovery work in solid tumors and clinical development plans for its RNA-based immunotherapies. — Katherine Lewin Alyssum Therapeutics emerges from stealth with $26M Series A: The Cambridge, MA-based biotech’s lead asset is AT-1965, a clinical-stage small molecule CMTR2 inhibitor. This round was led by co-founder Patrick Soon-Shiong and Accel, Famy and Navam Capital. — Katherine Lewin UK government pours £20M into dementia trial accelerator: The new initiative aims to increase the number of participants in late-stage dementia studies to the tens of thousands and “address pharma-identified roadblocks” to running the trials. The Dementia Trials Accelerator’s objectives include creating a biomarker toolbox and extending trial enrollment to community settings. — Ayisha Sharma

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025 Dose-limiting toxicities observed in rezatapopt and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) combination arm of Phase 1b PYNNACLE trial; rezatapopt 500 mg once-daily in combination with pembrolizumab 200 mg every three weeks established as maximum tolerated dose; due to limited clinical benefit at this dose, PMV is discontinuing enrollment in the Phase 1b combination arm PMV Pharmaceuticals is collaborating with MD Anderson Cancer Center (MDACC) and Memorial Sloan Kettering Cancer Center (MSK) to support an investigator-initiated Phase 1b study evaluating rezatapopt monotherapy and in combination with azacitidine in patients with recurrent or refractory AML/MDS harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today provided an update on the Phase 2 monotherapy and Phase 1b combination portions of the ongoing PYNNACLE clinical trial. PYNNACLE Phase 2 Monotherapy Update Enrollment is on track in the Phase 2 monotherapy portion of the PYNNACLE clinical trial. The multicenter, single-arm, registrational, tumor-agnostic Phase 2 trial is assessing rezatapopt as monotherapy at a dose of 2000 mg once-daily in patients with TP53 Y220C and KRAS wild-type advanced solid tumors. The primary endpoint of the trial is overall response rate per blinded independent central review. The trial is designed to enroll 114 patients across five cohorts at approximately 60 sites. More than 75% of sites have been activated across the U.S., Europe, and Asia-Pacific. PMV plans to provide data from the interim analysis of the Phase 2 monotherapy portion of the PYNNACLE trial by mid-2025 and anticipates submitting a New Drug Application by the end of 2026. PYNNACLE Phase 1b Rezatapopt in Combination with Pembrolizumab Update PMV has decided to discontinue enrollment in the Phase 1b combination arm of the PYNNACLE trial evaluating rezatapopt in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with advanced solid tumors harboring a TP53 Y220C mutation. Nineteen patients were enrolled in the combination arm of the trial. This decision was driven by dose-limiting toxicities (DLTs) observed at the 1000 mg dose of rezatapopt once-daily plus pembrolizumab 200 mg every three weeks. The DLTs were Grade 2 and 3 and included AST increase, platelet count decrease, pancreatitis, dehydration, and rash. No Grade 4 or 5 adverse events were observed. The safety profile of the rezatapopt and pembrolizumab combination has been consistent with each agent as monotherapy with no new safety signals observed. Per protocol, these observations established rezatapopt 500 mg once-daily in combination with pembrolizumab 200 mg every three weeks as the maximum tolerated dose. Patients dosed with rezatapopt 500 mg once-daily in combination with pembrolizumab did not experience a clinically meaningful benefit, informing the decision to discontinue enrollment in the combination arm of the PYNNACLE trial. MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center to Initiate a Phase 1b Study in Recurrent/Refractory AML/MDS PMV Pharma is collaborating with MD Anderson Cancer Center (MDACC) and Memorial Sloan Kettering Cancer Center (MSK) to support an investigator-initiated Phase 1b study. The study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of rezatapopt monotherapy and in combination with azacitidine in approximately 25 patients with recurrent or refractory acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) harboring a TP53 Y220C mutation. Enrollment is planned to begin in the first quarter of 2025 across two sites. “There is an important need for new treatment options for patients with recurrent or refractory AML or MDS harboring a TP53 Y220C mutation, as this mutation is often associated with poorer prognosis and resistance to conventional therapies” said Courtney DiNardo M.D., MSCE, Department of Leukemia, Division of Cancer Medicine at MDACC. “Based on proof-of-concept data demonstrating the ability of rezatapopt to selectively reactivate p53 in locally advanced/metastatic solid tumor patients with a TP53 Y220C mutation, we believe that rezatapopt in combination with azacitidine has the potential to significantly benefit this patient population.” Eytan M. Stein, M.D., Chief, Leukemia Service at MSK commented, “Patients with p53 mutant AML currently have no effective standard of care treatment options that lead to long term survival, so this important trial using rezatapopt is the first step in developing a focused, mutation specific strategy, for this patient population.” David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma commented, “While we are disappointed to discontinue enrollment of the trial evaluating rezatapopt in combination with pembrolizumab, we look forward to the initiation of the AML/MDS study and evaluating rezatapopt in other settings. I would like to thank the patients and investigators for their time and commitment to the Phase 1b combination portion of the PYNNACLE study. We remain excited by the potential for rezatapopt as a monotherapy in patients with advanced solid tumors harboring a TP53 Y220C mutation and KRAS wild-type and look forward to providing interim data in the middle of next year.” KEYTRUDA® (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. About Rezatapopt Rezatapopt (PC14586) is a first-in-class, small molecule p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration (FDA) granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a TP53 Y220C mutation. About the PYNNACLE Clinical Trial The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The primary objective of the Phase 1 portion of the trial was to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of rezatapopt when administered orally to patients. Safety, tolerability, pharmacokinetics, and effects on biomarkers were also assessed. In Phase 1, an overall response rate of 38% (6/16 evaluable patients) was achieved at the RP2D of 2000 mg daily reflective of the Phase 2 patient population (TP53 Y220C and KRAS wild-type). The median duration of response was seven months. The Phase 2 monotherapy portion is a registrational, single-arm, expansion basket clinical trial comprising five cohorts (ovarian, lung, breast, endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 Y220C and KRAS wild-type advanced solid tumors. For more information about the Phase 1/2 PYNNACLE clinical trial, refer to www.clinicaltrials.gov (NCT trial identifier NCT04585750). About PMV Pharma PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our future plans or expectations for rezatapopt, including our ability to obtain approval as a treatment option on a tumor-agnostic basis and as a monotherapy or in combination with other agents, expectations regarding timing for interim data readouts and success of the Phase 2 portion of the PYNNACLE trial, our expectation and timing of NDA filing(s) with the FDA for the current clinical trial for rezatapopt, the current and future enrollment of patients in our clinical trials, the timing, progress and activation of sites for our clinical trials, and plans for MDACC and MSKCC’s investigator-initiated study assessing rezatapopt as monotherapy and in combination with azacitidine for treatment of recurrent or refractory AML/MDS patients. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of our product candidate development activities and planned clinical trials, our ability to execute on our strategy and operate as a clinical stage company, the potential for clinical trials of rezatapopt or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results, our ability to fund operations, and the impact that a global pandemic, other public health emergencies or geopolitical tensions or conflicts may have on our clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on February 29, 2024, our Quarterly Report on Form 10-Q for the three months ended March 31, 2024, filed with the SEC on May 9, 2024, and our other filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investors Contact:Tim SmithSenior Vice President, Head of Corporate Development and Investor Relationsinvestors@pmvpharma.com Media Contact:Kathy VincentGreig Communicationskathy@greigcommunications.com

▎药明康德内容团队报道 根据即刻药数数据库，上周（9月9日~9月15日），全球生物制药领域至少14家致力于创新药研发的公司宣布完成新一轮融资，其中包含2家中国公司。这些最新获得资本市场青睐的新锐公司主要致力于多肽、抗体、耐药菌抗菌素、细胞和基因疗法、放射性药物等领域。 泽纳仕生物（Zenas BioPharma） 融资轮次：IPO 融资金额：2.25亿美元 9月13日，泽纳仕生物宣布在纳斯达克上市，并将首次公开发行股票（IPO）定价为每股17.00美元，预计募资总金额为2.25亿美元。泽纳仕生物成立于2021年，致力于开发免疫治疗药物。该公司于2023年获得1.18亿美元B轮融资，由Enavate Sciences领投，维梧资本等投资方跟投。 目前，泽纳仕生物正在开展CD19 x FcƳRIIB双特异性抗体obexelimab治疗IgG4相关疾病（IgG4-RD）和自身免疫疾病的临床研究。2023年9月，泽纳仕生物宣布就这款新药与百时美施贵宝公司达成合作，涉及5000万美元预付款以及其他潜在款项，后者还对其进行股权投资。泽纳仕生物另一款在研新药ZB001是靶向胰岛素样生长因子1受体（IGF-1R）的抗体药物，拟开发用于治疗甲状腺眼病。 贝斯生物 融资轮次：A2轮 融资金额：数千万元 9月13日，贝斯生物宣布完成数千万人民币的A2轮融资，由戈壁大湾区（Gobi Partners GBA）管理的AEF大湾区创业基金领投。此前，贝斯生物已累计获得了数千万美元的种子轮和A轮投资，并获得国际生物制药风险投资机构的支持。本轮融资将用于加强贝斯生物的研发团队、优化产品管线、加速临床试验，并为未来的商业化奠定坚实的基础。 贝斯生物成立于2021年，是一家专注于基因编辑领域基础创新的技术驱动型创新公司。自成立以来，该公司一直致力于开发创新的细胞疗法和基因编辑产品，用于治疗癌症和遗传疾病。今年7月，贝斯生物首款产品NK510——一款基于碱基编辑技术的自然杀伤细胞（NK）产品已经向中国NMPA申报IND并获得受理。除了NK510之外，贝斯生物的产品管线还包括多个针对血液恶性肿瘤和自身免疫疾病的碱基编辑NK细胞产品，以及通用CAR免疫疗法和体内基因编辑产品。 MBX Biosciences 融资轮次：IPO 融资金额：1.63亿美元 9月13日，专注于新型肽类药物研发的MBX Biosciences宣布于纳斯达克上市，公开发行价为每股16美元，总募资金额预计将达到1.632亿美元。今年8月，该公司刚刚完成由Deep Track Capital领投的6350万美元的C轮融资。 MBX Biosciences专注于发现和开发新型肽疗法，用于内分泌和代谢紊乱治疗。该公司的MBX 2109是一款甲状旁腺激素肽前体药物，已进入甲状旁腺功能减退症的2期临床试验，预计将于2025年三季度获得基线结果。另一款MBX 1416是用于减肥后低血糖的候选产品，正在进行1期研究。该公司还拥有肥胖和代谢性疾病的早期候选药物组合，其中长效GLP-1/GIP受体共激动剂前药MBX 4291正在推进IND申报。 Vironexis Biotherapeutics 融资轮次：种子轮 融资金额：2600万美元 9月13日，Vironexis Biotherapeutics宣布走出隐匿模式，推出其TransJoin腺相关病毒（AAV）基因疗法平台，并展示了血液癌症、预防实体瘤转移及癌症疫苗等十余款候选产品。Vironexis同时完成了2600万美元的种子轮融资，该轮融资由Drive Capital和Future Ventures领投，Moonshots Capital和Capital Factory参投。 Vironexis首个候选基因疗法VNX-101的IND申请已获得FDA许可，拟治疗CD19阳性急性淋巴细胞白血病。该公司计划2024年第四季度启动VNX-101的1/2期临床试验的患者入组工作。Vironexis的第二个项目VNX-202用于预防HER2阳性癌症的转移，计划在2025年启动1/2期临床试验。其他候选产品还包括治疗BCMA/GPRC5D阳性多发性骨髓瘤、CD19/20阳性B细胞淋巴瘤的产品；预防GD2阳性神经母细胞瘤、HER2阳性胃癌、PSMA阳性和MSLN阳性胰腺癌、B7H3阳性骨肉瘤和GP350阳性鼻咽癌的在研疗法。 PhoreMost 融资轮次：B轮 融资金额：1200万美元 9月11日，针对“不可成药”靶点开发蛋白降解等药物的PhoreMost公司宣布完成1200万美元B轮融资。PhoreMost成立于2014年，该公司正在基于“蛋白质干扰技术”开发下一代表型筛选平台，以识别未来治疗的新靶标。该公司的在研产品涉及癌症、衰老、靶向蛋白质降解等领域。最近几年，PhoreMost与包括罗氏（Roche）在内的多家公司达成研发合作。 Radiant Biotherapeutics 融资轮次：A轮 融资金额：3500万美元 9月11日，致力于开发抗体药物的Radiant Biotherapeutics宣布完成3500万美元的A轮融资，由比尔及梅琳达·盖茨基金会（Bill & Melinda Gates Foundation）和Amplitude Ventures共同领投。其他投资者包括加拿大商业发展银行投资部门BDC Capital，以及由abrdn公司管理的投资基金abrdn。现有投资者FACIT、Alexandria Venture Investments和多伦多创新加速合作伙伴（TIAP）也参与了本轮融资。本次融资将支持该公司主打项目4-1BB推进至临床试验开发阶段。 Radiant公司的专有Multabody平台旨在开发具“best-in-class”潜力的抗体疗法。Multabody平台通过增强靶标结合强度来克服现有抗体疗法的不足。此外，通过该平台所开发的抗体具多特异性，能靶向不同的致病蛋白以及同一靶标蛋白的多个表位。这些特性使Multabody平台所开发的疗法在治疗实体瘤、血液癌症、传染性疾病等多个治疗领域中展现出极强的效力。 PanTera 融资轮次：A轮 融资金额：9300万欧元 9月11日，PanTera宣布完成9300万欧元的超额A轮融资，以加速其放射性同位素锕-225（Ac-225）的生产。该轮融资由EQT Life Sciences领投，Kurma Partners、Eurazeo、Korys、Paladin和PMV等机构跟投。PanTera成立于2022年9月，致力于Ac-225的大规模生产，以提高基于Ac-225的潜在创新癌症疗法的可及性。 BioVersys 融资轮次：战略投资 融资金额：600万美元 9月11日，专注于研究和开发新型抗菌产品以治疗多药耐药性的细菌引起的严重危及生命的感染的BioVersys AG宣布获得600万美元战略投资，由Guangzhou Sino-Israel Bio-Industry Investment Fund 2 LLP (GIBF) 投资。该投资将扩大其产品管线BV100在中国的临床开发。 BioVersys AG专注于发现、开发和商业化新型抗菌产品，以治疗由多重耐药细菌引起的严重危及生命的感染。其主要研发项目与葛兰素史克（GSK）和法国里尔大学达成联盟合作，以解决了鲍曼不动杆菌（BV100，2期临床）和结核病（alpibectir，2a期临床）的医院感染问题。该公司的候选药物来自其内部技术平台——TRIC和Ansamycin Chemistry（安霉素化学），旨在克服耐药机制，阻断毒力产生，直接影响有害细菌的发病机制。BioVersys位于瑞士巴塞尔的生物技术中心。 Remedium Bio 融资轮次：未知轮 融资金额：未透露 9月10日，LifeSpan Vision Ventures宣布完成对Remedium Bio的投资。Remedium Bio是一家新型基因疗法开发公司。该公司正在开发一种可调剂量基因治疗平台，可以用单次注射、剂量可调的基因治疗取代广泛的多蛋白注射治疗。这种通过皮下注射进行的治疗更具安全、局部、持久优势，且成本低于许多蛋白质疗法。该轮融资将用于推动该公司主要候选产品RMD-1202进入1期研究。RMD-1202是GLP-1受体激动剂，其减肥、血糖控制和胰岛素反应优于每日GLP-1蛋白注射，具有潜在的安全性和耐受性。 君合盟生物 融资轮次：B+轮 融资金额：2亿元 9月10日，君合盟生物宣布完成超2亿元B+轮融资，由国投创合领投，弘盛资本、元禾控股、新氧集团、合君医药跟投。本轮融资资金将主要用于推进其在研管线开发，快产品管线产业化及商业化推广。君合盟生物专注于重组蛋白创新药物及合成生物学领域创新产品开发，管线围绕严肃医疗、消费医疗、代谢等蛋白药物领域，包括重组I/III型人胶原蛋白原液及制剂、重组A型肉毒毒素等。 Epsilogen 融资轮次：B轮 融资金额：1250万英镑 9月10日，致力于开发治疗癌症的新型免疫球蛋白 E (IgE) 抗体的Epsilogen公司宣布完成1250英镑的B轮融资。2023年7月，该公司公布了其IgE抗体MOv18 IgE治疗表达叶酸受体-α的晚期实体瘤患者的1期临床试验的积极数据。 Candid Therapeutics 融资轮次：A轮 融资金额：3.7亿美元 9月10日，Candid Therapeutics宣布走出隐匿模式，通过合并和融资收购了Vignette Bio和TRC 2004，囊获两款T细胞连接器（TCE）管线，并同时完成超过3.7亿美元融资，以加速推动自身免疫疾病创新疗法的开发。此次融资由Venrock Healthcare Capital Partners、Fairmount、TCGX和venBio Partners共同领投，此外还有其他多家投资者参投。 Candid公司正在开发能够清除特定B淋巴细胞群的TCE抗体，以推进这类新型疗法在自身免疫疾病领域的应用。该公司旗下的两款TCE抗体包含来自Vignette Bio的BCMA x CD3双特异性抗体CND106，以及来自TRC 2004的CD20 x CD3双特异性抗体CND261。CND106和CND261都已完成了1期剂量递增研究。该公司新闻稿指出，这两种药物均具有成为针对各种自身免疫疾病“best-in-class”疗法的潜力。 Bambusa Therapeutics 融资轮次：种子轮 融资金额：1500万美元 9月9日消息，Bambusa Therapeutics完成约1500万美元种子轮融资，由BVF Partners L.P.和KKR旗下的Dawn Biopharma共同领投，Salvia GmbH和渶策资本（INCE Capital）跟投。本轮融资筹集的资金将用于加速其双特异性抗体管线的开发及1期临床研究的推进。公开信息显示，Bambusa的首席执行官兼联合创始人为徐姗姗博士。该公司专注于开发双特异性抗体疗法，以治疗免疫和炎症疾病。 Superluminal Medicines 融资轮次：A轮 融资金额：1.2亿美元 9月9日，Superluminal Medicines 宣布完成 1.2 亿美元的A轮融资，由RA Capital Management领投，Insight Partners、NVentures、礼来、Gaingels等参投。本次融资将支持其先导项目进入临床开发，并增加G蛋白偶联受体（GPCR）小分子药物管线。Superluminal Medicines致力于开发差异化的研发管线，以改变药物发现的速度和准确性。该公司利用深度生物学和化学专业知识、机器学习和专有数据基础设施的全面结合，以快速发现候选化合物。 希望在资本市场的助力下，更多前沿技术和创新疗法可以尽快造福病患。 参考资料： [1]各家公司官网及公开资料 本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。